SRR10900571
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.700
- INTERFERON_GAMMA_RESPONSE+0.700
- ALLOGRAFT_REJECTION+0.600
- IL6_JAK_STAT3_SIGNALING+0.500
- INFLAMMATORY_RESPONSE+0.500
- COMPLEMENT+0.400
- IL2_STAT5_SIGNALING+0.400
- KRAS_SIGNALING_UP+0.400
- TGF_BETA_SIGNALING+0.400
- TNFA_SIGNALING_VIA_NFKB+0.400
Top 10 suppressed
- MYC_TARGETS_V2-0.600
- E2F_TARGETS-0.500
- MYC_TARGETS_V1-0.500
- G2M_CHECKPOINT-0.300
- OXIDATIVE_PHOSPHORYLATION-0.300
- SPERMATOGENESIS-0.300
- APICAL_SURFACE-0.200
- CHOLESTEROL_HOMEOSTASIS-0.200
- DNA_REPAIR-0.200
- GLYCOLYSIS-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SAMN03290930 | — | — | 0.891 |
| 2 | SRR5088910 | — | — | 0.888 |
| 3 | 6bf9821d-da67-470f-9650-69d05b056166 | — | — | 0.881 |
| 4 | SRR8518216 | — | D | 0.872 |
| 5 | BS_49VCQD19 | Neurofibroma | — | 0.868 |
| 6 | TCGA-OR-A5JO-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.858 |
| 7 | MNG991 | — | — | 0.856 |
| 8 | MNG464 | — | — | 0.853 |
| 9 | TCGA-A8-A096-01A-11R-A00Z-07 | — | B | 0.851 |
| 10 | 98e49cc4-1040-4291-b975-da3e8fc3ddfc | — | — | 0.849 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.700 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.700 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.600 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.500 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.500 | Idelalisib | — uncovered |
| COMPLEMENT | 0.400 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.400 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.400 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.400 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.400 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.400 | Inavolisib | — uncovered |
| APOPTOSIS | 0.300 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.200 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |
| P53_PATHWAY | 0.100 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.100 | Remibrutinib | — uncovered |